WO2016135740A1 - Process for preparing stable oral compositions of everolimus - Google Patents
Process for preparing stable oral compositions of everolimus Download PDFInfo
- Publication number
- WO2016135740A1 WO2016135740A1 PCT/IN2015/000182 IN2015000182W WO2016135740A1 WO 2016135740 A1 WO2016135740 A1 WO 2016135740A1 IN 2015000182 W IN2015000182 W IN 2015000182W WO 2016135740 A1 WO2016135740 A1 WO 2016135740A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- everolimus
- pharmaceutically acceptable
- drug solution
- granules
- solvents
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
Definitions
- the present invention relates to a process for preparing stable solid oral compositions comprising 40-O-(2- hydroxy) ethyl-Rapamycin or its pharmaceutically acceptable salts thereof:
- Everolimus is chemically designated as (1R,9S,12S,15R,16E,18R,19R,21R, 23S,24E,26E, 28E,30S,32S,35R)-l,18-dihydroxy-12- ⁇ (lR)-2-[(l S,3R,4R)-4-(2- hydroxyethoxy)-3 -methoxy cyclohexyl] - 1 -methylethyl ⁇ - 19,30-dimethoxy-
- Everolimus is available as oral tablets with the name of Afinitor® for the treatment of tumour diseases, and under the name of Zortress® for the prevention of organ rejection.
- U.S. Patent No. 5665772 disclose Everolimus.
- U.S. Patent No. 6004973 disclosed pharmaceutical compositions in the form of solid dispersion comprising 40-O-(2 -hydroxy) ethyl-Rapamycin (Everolimus, RADOOl) and a carrier medium. These compositions provide high bioavailability of drug substance, convenient to administer and are stable.
- U.S. Patent No. 8617598 disclosed oral pharmaceutical compositions comprising solid dispersion of 40-O-(2-hydroxy) ethyl-Rapamycin, a disintegrant comprising cross- linked polyvinyl pyrrolidone and colloidal silicon dioxide.
- Solid dispersion is complex process, involves higher quantity of solvents and higher cost for preparation, there is a need to develop alternative stable compositions of Everolimus using simplified and robust process, which is cost effective and having good dissolution rates and bioavailability. Accordingly, inventors of the present invention have developed a simple process for preparing stable oral compositions of Everolimus.
- the present invention relates to a process for preparing stable oral compositions comprising Everolimus and. one or more pharmaceutically acceptable excipients.
- the present invention particularly relates to a wet granulation process for preparing stable oral compositions comprising Everolimus and one or more pharmaceutically acceptable excipients.
- One embodiment of the present invention provides a process for preparing composition comprising Everolimus and one or more pharmaceutically acceptable excipients by wet granulation using drug solution.
- Another embodiment of the present invention provides a process for preparing composition comprising Everolimus and one or more pharmaceutically acceptable excipients by wet granulation using drug solution obtained by dissolving Everolimus in one or more pharmaceutically acceptable solvents.
- Another embodiment of the present invention provides a wet granulation process for preparing stable oral compositions of everolimus comprising the steps of: (a) sifting one or more pharmaceutically acceptable excipients, (b) dissolving Everolimus in solvent and (or) mixture of solvents to form drug solution, (c) granulating the dry mix of step (a) with the drug solution of step (b) to obtain wet mass, (d) drying and sieving the wet mass to obtain granules, (e) blending the granules with extra granular excipients followed by lubrication and (f) compressing the lubricated blend into tablets or filled into capsules.
- Another embodiment of the present invention provides a process for preparation of stable oral compositions of everolimus comprising the steps of: (a) sifting one or more pharmaceutically acceptable excipients, (b) dissolving Everolimus in solvent and (or) mixture of solvents to form drug solution, (c) suspending one or more pharmaceutically acceptable excipients in to drug solution to form suspension, (d) granulating the dry mix of step (a) with the suspension of step (c) to obtain wet mass, (e) drying and sieving the wet mass to obtain granules, (f) blending the granules with extra granular excipients, followed by lubrication, and (g) compressing the lubricated blend into tablets or filled into capsules.
- the present invention relates to a process for preparing stable oral compositions comprising Everolimus and one or more pharmaceutically acceptable excipients.
- the present invention relates to a wet granulation process for preparing stable oral compositions comprising Everolimus and one or more pharmaceutically acceptable excipients.
- the present invention relates to a wet granulation process for preparing stable oral compositions comprising Everolimus and one or more pharmaceutically acceptable excipients using drug solution.
- drug solution includes solution obtained by dissolving Everolimus or its pharmaceutically acceptable salt thereof in solvent and (or) mixture of solvents.
- One embodiment the present invention provides adding one or more pharmaceutically acceptable excipients in drug solution to form a suspension.
- Epolimus or 40-O-(2-hydroxy)ethyl-Rapamycin as used herein according to the present invention includes, Everolimus in the form of free base, a pharmaceutically acceptable salt thereof, amorphous Everolimus, crystalline Everolimus, any isomer, derivative, hydrate, solvate or prodrug or a combination thereof.
- composition or “solid oral composition” or “dosage form” or “pharmaceutical composition” as used herein synonymously include solid dosage forms such as tablets, capsules, powder, particles, granules, pellets, mini-tablets and the like meant for oral administration.
- a “composition” comprises an active pharmaceutical ingredient and at least one pharmaceutically acceptable excipient.
- drug herein refers to Everolimus or a pharmaceutically acceptable salt thereof.
- pharmaceutically acceptable excipient includes a pharmaceutically acceptable material such as diluents, disintegrates, binders, lubricants, antioxidants, and the like, suitable for administering an active pharmaceutical ingredient. Each excipient should be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient.
- Another embodiment of the present invention provides a wet granulation process for preparing stable oral compositions of everolimus comprising the steps of: (a) sifting one or more pharmaceutically acceptable excipients, (b) dissolving Everolimus in solvent and (or) mixture of solvents to form drug solution, (c) granulating the dry mix of step (a) with the drug solution of step (b) to obtain wet mass, (d) drying and sieving the wet mass to obtain granules, (e) blending the granules of step (d) with extra granular excipients if any, followed by lubrication and (f) compressing the lubricated blend of step (e) into tablets or filled into capsules.
- Another embodiment of the present invention provides a wet granulation process for preparing stable oral compositions of everolimus comprising the steps of: (a) sifting one or more pharmaceutically acceptable excipients, (b) dissolving Everolimus in solvent and (or) mixture of solvents to form drug solution, (c) suspending one or more pharmaceutically acceptable excipients in to drug solution to form a suspension, (d) granulating the dry mix of step (a) with the suspension of step (c) to obtain wet mass, (e) drying and sieving the wet mass to obtain granules, (f) blending the granules of step (e) with extra granular excipients if any, followed by lubrication, and (g) compressing the lubricated blend of step (f) into tablets or filled into capsules.
- solvents suitable for processing the pharmaceutical compositions include one or more of organic solvents such as organic solvents such as an alcohol, for example methanol, ethanol, or isopropanol; an ester, e.g. ethyl acetate; an ether, e.g. diethyl ether; a ketone, e.g. acetone; or a halogenated hydrocarbon, e.g. dichloroethane and mixtures thereof.
- organic solvents such as an alcohol, for example methanol, ethanol, or isopropanol
- an ester e.g. ethyl acetate
- an ether e.g. diethyl ether
- a ketone e.g. acetone
- halogenated hydrocarbon e.g. dichloroethane and mixtures thereof.
- Suitable excipients include but are not limited to antioxidants, diluents, binders, disintegrants and lubricants.
- Antioxidants include, but are not limited to butylated hydroxytoluene (BHT), Butylated hydroxy anisole, tocopherols, ascorbic acid derivatives, propyl gallate and fumaric acid and mixtures thereof.
- BHT butylated hydroxytoluene
- Butylated hydroxy anisole butylated hydroxy anisole
- tocopherols butylated hydroxy anisole
- ascorbic acid derivatives propyl gallate and fumaric acid and mixtures thereof.
- Diluents, fillers, or bulking agents for this purpose include, but are not limited to lactose, microcrystalline cellulose, dibasic calcium phosphate, calcium phosphate, powdered cellulose, dextrates, isomalt, calcium carbonate, magnesium carbonate, starch, pre-gelatinized starch, and mixtures thereof.
- Binders include, but are not limited to hydroxypropyl methylcellulose, hydroxypropyl cellulose, polyvinylpyrrolidone (povidone), gum arabic and sugars such as sucrose, glucose, dextrose, lactose, polyvinyl alcohol and mixtures thereof.
- Disintegrants include, but are not limited to crospovidone, croscarmellose sodium, starch, potato starch, pregelatinized starch, corn starch, sodium starch glycolate, microcrystalline cellulose, low substituted hydroxypropyl cellulose and mixtures thereof.
- Suitable lubricants include but are not limited to fatty acids, fatty acid salts, and fatty acid esters such as magnesium stearate, calcium stearate, stearic acid, sodium stearyl fumarate, hydrogenated vegetable oil and mixtures thereof.
- Example 1 Tablet compositions of Everolimus prepared by wet granulation method
- step (3) Obtained suspension of step (3) was added to anhydrous lactose in granulator bowl to obtain wet mass
- step (4) was dried, sifted and milled to obtain granules
- step (5) Obtained granules of step (5) were blended with extra granular crospovidone and lubricated with magnesium stearate 7.
- the lubricated blend of step (6) was finally filled into capsules or compressed into tablets.
- Example 2 Tablet compositions of Everolimus prepared by wet granulation method
- step (4) was added to dry blend of step (1) in granulator bowl to obtain wet mass
- step (5) Wet mass of step (5) was dried, sifted and milled to obtain granules
- step (6) Obtained granules of step (6) were mixed with extra granular anhydrous lactose, crospovidone and lubricated with magnesium stearate
- Example 3 Tablet compositions of Everolimus prepared by wet granulation method
- step (2) Blend of step (2) was granulated with drug solution of step (1) to form granules which are dried and milled
- Milled Granules of step (3) were blended with extra granular anhydrous lactose, crospovidone and lubricated with magnesium stearate
- step (4) The lubricated blend of step (4) was finally filled into capsules or compressed into tablets.
- Dissolution test was performed for tablets prepared as per the Examples 1, 2, 3 Comparative reference (Afinitor), using USP apparatus type II, at 50 rpm, in 500 ri purified water with 0.4 % sodium lauryl sulphate. (Cumulative % drug dissolved)
- tablets prepared according to the present invention were acceptable.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Process for preparing composition comprising Everolimus or its pharmaceutically acceptable salts and one or more pharmaceutically acceptable excipients by wet granulation by dissolving Everolimus in one or more pharmaceutically acceptable solvents.
Description
PROCESS FOR PREPARING STABLE ORAL COMPOSITIONS OF EVEROLIMUS
FIELD OF THE INVENTION:
The present invention relates to a process for preparing stable solid oral compositions comprising 40-O-(2- hydroxy) ethyl-Rapamycin or its pharmaceutically acceptable salts thereof:
BACKGROUND OF THE INVENTION:
Everolimus is chemically designated as (1R,9S,12S,15R,16E,18R,19R,21R, 23S,24E,26E, 28E,30S,32S,35R)-l,18-dihydroxy-12-{(lR)-2-[(l S,3R,4R)-4-(2- hydroxyethoxy)-3 -methoxy cyclohexyl] - 1 -methylethyl } - 19,30-dimethoxy-
15,17,21 ,23,29,35-hexamethyl-l l,36-dioxa-4-aza-tricyclo[30.3.1.04,9] hexatriaconta- 16,24,26,28-tetraene-2,3,10,14,20-pentaone with structural formula as follows.
In the United States, Everolimus is available as oral tablets with the name of Afinitor® for the treatment of tumour diseases, and under the name of Zortress® for the prevention of organ rejection. U.S. Patent No. 5665772 disclose Everolimus.
U.S. Patent No. 6004973 disclosed pharmaceutical compositions in the form of solid dispersion comprising 40-O-(2 -hydroxy) ethyl-Rapamycin (Everolimus, RADOOl) and a carrier medium. These compositions provide high bioavailability of drug substance, convenient to administer and are stable.
U.S. Patent No. 8617598 disclosed oral pharmaceutical compositions comprising solid dispersion of 40-O-(2-hydroxy) ethyl-Rapamycin, a disintegrant comprising cross- linked polyvinyl pyrrolidone and colloidal silicon dioxide. However Solid dispersion is complex process, involves higher quantity of solvents and higher cost for preparation, there is a need to develop alternative stable compositions of Everolimus using simplified and robust process, which is cost effective and having good dissolution rates and bioavailability. Accordingly, inventors of the present invention have developed a simple process for preparing stable oral compositions of Everolimus.
SUMMARY OF THE INVENTION:
The present invention relates to a process for preparing stable oral compositions comprising Everolimus and. one or more pharmaceutically acceptable excipients.
The present invention particularly relates to a wet granulation process for preparing stable oral compositions comprising Everolimus and one or more pharmaceutically acceptable excipients.
One embodiment of the present invention provides a process for preparing composition comprising Everolimus and one or more pharmaceutically acceptable excipients by wet granulation using drug solution.
Another embodiment of the present invention provides a process for preparing composition comprising Everolimus and one or more pharmaceutically acceptable excipients by wet granulation using drug solution obtained by dissolving Everolimus in one or more pharmaceutically acceptable solvents.
Another embodiment of the present invention provides a wet granulation process for preparing stable oral compositions of everolimus comprising the steps of: (a) sifting one or more pharmaceutically acceptable excipients, (b) dissolving Everolimus in solvent and (or) mixture of solvents to form drug solution, (c) granulating the dry mix of step (a) with the drug solution of step (b) to obtain wet mass, (d) drying and sieving the wet mass to obtain granules, (e) blending the granules with extra granular excipients followed by lubrication and (f) compressing the lubricated blend into tablets or filled into capsules.
Another embodiment of the present invention provides a process for preparation of stable oral compositions of everolimus comprising the steps of: (a) sifting one or more pharmaceutically acceptable excipients, (b) dissolving Everolimus in solvent and (or) mixture of solvents to form drug solution, (c) suspending one or more pharmaceutically acceptable excipients in to drug solution to form suspension, (d) granulating the dry mix of step (a) with the suspension of step (c) to obtain wet mass, (e) drying and sieving the wet mass to obtain granules, (f) blending the granules with extra granular excipients, followed by lubrication, and (g) compressing the lubricated blend into tablets or filled into capsules.
DETAILED DESCRIPTION OF THE INVENTION:
The present invention relates to a process for preparing stable oral compositions comprising Everolimus and one or more pharmaceutically acceptable excipients.
Preferably, the present invention relates to a wet granulation process for preparing stable oral compositions comprising Everolimus and one or more pharmaceutically acceptable excipients. More preferably the present invention relates to a wet granulation process for preparing stable oral compositions comprising Everolimus and one or more pharmaceutically acceptable excipients using drug solution.
The term "drug solution" as used herein according to the present invention includes solution obtained by dissolving Everolimus or its pharmaceutically acceptable salt thereof in solvent and (or) mixture of solvents.
One embodiment the present invention provides adding one or more pharmaceutically acceptable excipients in drug solution to form a suspension.
The term "Everolimus or 40-O-(2-hydroxy)ethyl-Rapamycin" as used herein according to the present invention includes, Everolimus in the form of free base, a pharmaceutically acceptable salt thereof, amorphous Everolimus, crystalline Everolimus, any isomer, derivative, hydrate, solvate or prodrug or a combination thereof.
The term "composition" or "solid oral composition" or "dosage form" or "pharmaceutical composition" as used herein synonymously include solid dosage forms such as tablets, capsules, powder, particles, granules, pellets, mini-tablets and the like meant for oral administration. A "composition" comprises an active pharmaceutical ingredient and at least one pharmaceutically acceptable excipient.
The term "drug" herein refers to Everolimus or a pharmaceutically acceptable salt thereof.
The term "pharmaceutically acceptable excipient" includes a pharmaceutically acceptable material such as diluents, disintegrates, binders, lubricants, antioxidants, and the like, suitable for administering an active pharmaceutical ingredient. Each excipient should be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient.
Another embodiment of the present invention provides a wet granulation process for preparing stable oral compositions of everolimus comprising the steps of: (a) sifting one or more pharmaceutically acceptable excipients, (b) dissolving Everolimus in solvent and (or) mixture of solvents to form drug solution, (c) granulating the dry mix of step (a) with the drug solution of step (b) to obtain wet mass, (d) drying and sieving the wet mass to obtain granules, (e) blending the granules of step (d) with extra granular excipients if any, followed by lubrication and (f) compressing the lubricated blend of step (e) into tablets or filled into capsules.
Another embodiment of the present invention provides a wet granulation process for preparing stable oral compositions of everolimus comprising the steps of: (a) sifting one or more pharmaceutically acceptable excipients, (b) dissolving Everolimus in solvent and (or) mixture of solvents to form drug solution, (c) suspending one or more pharmaceutically acceptable excipients in to drug solution to form a suspension, (d) granulating the dry mix of step (a) with the suspension of step (c) to obtain wet mass, (e) drying and sieving the wet mass to obtain granules, (f) blending the granules of step (e) with extra granular excipients if any, followed by lubrication, and (g) compressing the lubricated blend of step (f) into tablets or filled into capsules.
According to the present invention, solvents suitable for processing the pharmaceutical compositions include one or more of organic solvents such as organic solvents such as an alcohol, for example methanol, ethanol, or isopropanol; an ester, e.g.
ethyl acetate; an ether, e.g. diethyl ether; a ketone, e.g. acetone; or a halogenated hydrocarbon, e.g. dichloroethane and mixtures thereof.
Various useful excipients include but are not limited to antioxidants, diluents, binders, disintegrants and lubricants.
Antioxidants include, but are not limited to butylated hydroxytoluene (BHT), Butylated hydroxy anisole, tocopherols, ascorbic acid derivatives, propyl gallate and fumaric acid and mixtures thereof.
Diluents, fillers, or bulking agents for this purpose include, but are not limited to lactose, microcrystalline cellulose, dibasic calcium phosphate, calcium phosphate, powdered cellulose, dextrates, isomalt, calcium carbonate, magnesium carbonate, starch, pre-gelatinized starch, and mixtures thereof.
Binders include, but are not limited to hydroxypropyl methylcellulose, hydroxypropyl cellulose, polyvinylpyrrolidone (povidone), gum arabic and sugars such as sucrose, glucose, dextrose, lactose, polyvinyl alcohol and mixtures thereof. Disintegrants include, but are not limited to crospovidone, croscarmellose sodium, starch, potato starch, pregelatinized starch, corn starch, sodium starch glycolate, microcrystalline cellulose, low substituted hydroxypropyl cellulose and mixtures thereof.
Suitable lubricants include but are not limited to fatty acids, fatty acid salts, and fatty acid esters such as magnesium stearate, calcium stearate, stearic acid, sodium stearyl fumarate, hydrogenated vegetable oil and mixtures thereof.
EXAMPLES
The following examples further describe and demonstrate particular embodiments within the scope of the present invention. The examples are given solely for illustration and are not to be construed as limitations as many variations are possible without departing from spirit and scope of the invention.
Example 1: Tablet compositions of Everolimus prepared by wet granulation method
*qs: quantity sufficient
Preparation method:
1. BHT, Everolimus in acetone were dissolved under stirring to form drug solution
2. Hydroxypropyl methylcellulose was dispersed in drug solution of step (1) under stirring to form a suspension
3. Dehydrated alcohol was added to suspension of step (2)
4. Obtained suspension of step (3) was added to anhydrous lactose in granulator bowl to obtain wet mass
5. Wet mass of step (4) was dried, sifted and milled to obtain granules
6. Obtained granules of step (5) were blended with extra granular crospovidone and lubricated with magnesium stearate
7. The lubricated blend of step (6) was finally filled into capsules or compressed into tablets.
Example 2: Tablet compositions of Everolimus prepared by wet granulation method
qs: quantity sufficient
Preparation method:
1. Intra granular anhydrous lactose and crospovidone were mixed to form dry blend
2. BHT, Everolimus in acetone were dissolved under stirring to form drug solution
3. Hydroxypropyl methylcellulose and lactose monohydrate were dispersed in step (2) under stirring to form a suspension
4. Dehydrated alcohol was added to suspension of step (3)
5. Obtained suspension of step (4) was added to dry blend of step (1) in granulator bowl to obtain wet mass
6. Wet mass of step (5) was dried, sifted and milled to obtain granules
7. Obtained granules of step (6) were mixed with extra granular anhydrous lactose, crospovidone and lubricated with magnesium stearate
8. The lubricated blend of step (7) was finally filled into capsules or compressed into tablets.
Example 3: Tablet compositions of Everolimus prepared by wet granulation method
*qs: quantity sufficient
Preparation method:
1. BHT, Everolimus in acetone were dissolved under stirring to form drug solution
2. Intragranular anhydrous lactose and Hydroxypropyl methylcellulose were transferred in to granulator bowl and blended
3. Blend of step (2) was granulated with drug solution of step (1) to form granules which are dried and milled
4. Milled Granules of step (3) were blended with extra granular anhydrous lactose, crospovidone and lubricated with magnesium stearate
5. The lubricated blend of step (4) was finally filled into capsules or compressed into tablets.
Comparative study on dissolution time:
Dissolution test was performed for tablets prepared as per the Examples 1, 2, 3 Comparative reference (Afinitor), using USP apparatus type II, at 50 rpm, in 500 ri purified water with 0.4 % sodium lauryl sulphate.
(Cumulative % drug dissolved)
Time in min Afinitor Example 1 Example 2 Example 3
10 96.6 93.1 80.0 86
20 100.5 101.1 93.0 97.1
30 100.0 103.6 96.0 100.4
45 99.1 105.1 97.0 102.2
Based on the dissolution data, tablets prepared according to the present invention were acceptable.
Claims
1. A process for preparing stable oral composition comprising Everolimus or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein the process is wet granulation.
2. The process according to claim 1, wherein the process comprises wet granulation using drug solution.
3. The drug solution according to claim 1, is prepared by dissolving drug in one or more pharmaceutically acceptable solvents.
4. The solvents according to claim 3, includes organic solvents such as an alcohol, for example methanol, ethanol, or isopropanol; an ester, e.g. ethyl acetate; ,an ether, e.g. diethyl ether; a ketone, e.g. acetone; or a halogenated hydrocarbon, e.g. dichloroethane and mixtures thereof.
5. The pharmaceutical composition according to claim 1, wherein the pharmaceutically acceptable excipients are selected from antioxidants, diluents, binders, disintegrants, lubricants or a mixture thereof.
6. The process according to claim 1, wherein the composition is in the form of capsules, tablets, MUPS, granules, pellets, solid dispersions, beads, particles, mini- tablets, and the like.
7. Wet granulation process for preparing stable oral compositions of everolimus comprising the steps of: (a) sifting one or more pharmaceutically acceptable excipients, (b) dissolving Everolimus in solvent and (or) mixture of solvents to form drug solution, (c) granulating the dry mix of step (a) with the drug solution of step (b) to obtain wet mass, (d) drying and sieving the wet mass to obtain
granules, (e) blending the granules of step (d) with extra granular excipients if any, followed by lubrication and (f) compressing the lubricated blend of step (e) into tablets or filled into capsules.
8. Wet granulation process for preparing stable oral compositions of everolimus comprising the steps of: (a) sifting one or more pharmaceutically acceptable excipients, (b) dissolving Everolimus in solvent and (or) mixture of solvents to form drug solution, (c) suspending one or more pharmaceutically acceptable excipients in to drug solution to form a suspension, (d) granulating the dry mix of step (a) with the suspension of step (c) to obtain wet mass, (e) drying and sieving the wet mass to obtain granules, (f) blending the granules of step (e) with extra granular excipients if any, followed by lubrication, and (g) compressing the lubricated blend of step (f) into tablets or filled into capsules.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN839/CHE/2015 | 2015-02-23 | ||
| IN839CH2015 | 2015-02-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2016135740A1 true WO2016135740A1 (en) | 2016-09-01 |
Family
ID=53716536
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IN2015/000182 WO2016135740A1 (en) | 2015-02-23 | 2015-04-23 | Process for preparing stable oral compositions of everolimus |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2016135740A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117982495A (en) * | 2024-04-07 | 2024-05-07 | 国药集团川抗制药有限公司 | Everolimus solid dispersion, preparation method thereof and everolimus tablet |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5665772A (en) | 1992-10-09 | 1997-09-09 | Sandoz Ltd. | O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants |
| US6004973A (en) | 1995-07-14 | 1999-12-21 | Novartis Ag | Pharmaceutical compositions comprising rafamycin coprecipitates |
| CN102138903B (en) * | 2011-03-17 | 2012-12-12 | 苏州特瑞药业有限公司 | Everolimus solid oral medicinal composition |
| WO2013022201A1 (en) * | 2011-08-11 | 2013-02-14 | Dong-A Pharm. Co., Ltd. | Process of preparing a stabilized and solubilized formulation of sirolimus derivatives |
| US8617598B2 (en) | 2001-09-28 | 2013-12-31 | Novartis Ag | Pharmaceutical compositions comprising colloidal silicon dioxide |
| CN103610646A (en) * | 2013-12-05 | 2014-03-05 | 江苏奥赛康药业股份有限公司 | Composition containing everolimus and preparation method thereof, and pharmaceutical preparation containing composition |
| WO2014186581A1 (en) * | 2013-05-15 | 2014-11-20 | Tobira Therapeutics, Inc. | Cenicriviroc compositions and methods of making and using the same |
-
2015
- 2015-04-23 WO PCT/IN2015/000182 patent/WO2016135740A1/en active Application Filing
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5665772A (en) | 1992-10-09 | 1997-09-09 | Sandoz Ltd. | O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants |
| US6004973A (en) | 1995-07-14 | 1999-12-21 | Novartis Ag | Pharmaceutical compositions comprising rafamycin coprecipitates |
| US8617598B2 (en) | 2001-09-28 | 2013-12-31 | Novartis Ag | Pharmaceutical compositions comprising colloidal silicon dioxide |
| CN102138903B (en) * | 2011-03-17 | 2012-12-12 | 苏州特瑞药业有限公司 | Everolimus solid oral medicinal composition |
| WO2013022201A1 (en) * | 2011-08-11 | 2013-02-14 | Dong-A Pharm. Co., Ltd. | Process of preparing a stabilized and solubilized formulation of sirolimus derivatives |
| WO2014186581A1 (en) * | 2013-05-15 | 2014-11-20 | Tobira Therapeutics, Inc. | Cenicriviroc compositions and methods of making and using the same |
| CN103610646A (en) * | 2013-12-05 | 2014-03-05 | 江苏奥赛康药业股份有限公司 | Composition containing everolimus and preparation method thereof, and pharmaceutical preparation containing composition |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117982495A (en) * | 2024-04-07 | 2024-05-07 | 国药集团川抗制药有限公司 | Everolimus solid dispersion, preparation method thereof and everolimus tablet |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101840182B1 (en) | Pharmaceutical compositions comprising 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactate monohydrate | |
| JP6216325B2 (en) | Pharmaceutical formulation | |
| JP2010519201A (en) | Controlled release formulation containing cilostazol and method for producing the same | |
| WO2015132708A1 (en) | Pharmaceutical composition of roflumilast | |
| KR20190015329A (en) | A pharmaceutical composition of a dapagliflozin co-crystal | |
| TWI418370B (en) | Dissolution-stable pharmaceutical agent | |
| KR20160000762A (en) | Composite formulation for oral administration comprising ezetimibe and rosuvastatin and a process for the preparation thereof | |
| WO2011051967A2 (en) | Pharmaceutical compositions comprising mycophenolate and processes for preparing thereof | |
| JP7117975B2 (en) | Pharmaceutical composition containing teneligliptin, method for producing pharmaceutical composition containing teneligliptin, tablet containing teneligliptin, and method for producing tablet containing teneligliptin | |
| EP3925601B1 (en) | Gastro-resistant formulation containing posaconazole and a polymeric precipitation inhibitor | |
| WO2016079687A1 (en) | Oral pharmaceutical composition of teriflunomide | |
| EP2701689B1 (en) | Pharmaceutical compositions of raltegravir, methods of preparation and use thereof | |
| AU2017244982A1 (en) | Film-coated tablet having high chemical stability of active ingredient | |
| WO2016135740A1 (en) | Process for preparing stable oral compositions of everolimus | |
| WO2014115082A1 (en) | Pharmaceutical formulations of imatinib | |
| KR101938872B1 (en) | Composition comprising complex for prevention and treatment of dementia and cognitive impairment | |
| JP2019156845A (en) | Stable pharmaceutical compositions comprising antibacterial agent | |
| EP3171861A1 (en) | Solid pharmaceutical composition comprising pi3k-inhibitor | |
| US20200093804A1 (en) | Pharmaceutical composition of everolimus | |
| WO2020003196A1 (en) | Pharmaceutical composition of axitinib | |
| WO2019170244A1 (en) | Ticagrelor—containing tablet formulation | |
| WO2016139681A2 (en) | Pharmaceutical composition of tizanidine and process for preparing the same | |
| WO2022029798A1 (en) | Pharmaceutical compositions comprising ribociclib | |
| US20210275546A1 (en) | High drug load solid oral dosage forms of dexamethasone | |
| WO2024171019A1 (en) | Pharmaceutical composition of trametinib and process of preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15739686 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 15739686 Country of ref document: EP Kind code of ref document: A1 |